Novartis lifts guidance again as demand climbs for top drugs
Novartis has boosted its 2024 outlook for a second time this year, thanks to strong sales for some of its biggest drugs used to treat heart failure and other ailments.
Novartis has boosted its 2024 outlook for a second time this year, thanks to strong sales for some of its biggest drugs used to treat heart failure and other ailments.
